Kirk Robarge

GDC-0449—A potent inhibitor of the hedgehog pathway

Kirk Robarge, Shirley A. Brunton, Georgette M. Castanedo et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 387 citations · Full text

Pharmacy, Life Sciences, Medicinal Chemistry +10

Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance

Gerrit J.P. Dijkgraaf, Bruno Alicke, Lasse Weinmann et al. · Cancer Research · 2010 · 363 citations · Full text

Medicine, Oncology, Pharmacology +13

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition

Aaron Boudreau, Hans E. Purkey, A. Hitz et al. · Nature Chemical Biology · 2016 · 268 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

Discovery of (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

James F. Blake, Michael Burkard, Jocelyn Chan et al. · Journal of Medicinal Chemistry · 2016 · 158 citations · Full text

Medicine, Oncology, Pharmacology +17

From Peptide to Non-Peptide. 2. The de Novo Design of Potent, Non-peptidal Inhibitors of Platelet Aggregation Based on a Benzodiazepinedione Scaffold

Robert S. McDowell, Brent Blackburn, Thomas R. Gadek et al. · Journal of the American Chemical Society · 1994 · 99 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13